Phase 2/3CompletedAge-related condition
MARS - Monitored Atherosclerosis Regression Study
A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease
- Sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 270 planned
- Conditions
- Atherosclerosis; Coronary Artery Disease
- Interventions
- lovastatin
- Ages
- adults, older adults
- Registry
- NCT00116870
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
Primary outcomes
- the average (per-patient) change from baseline in percent diameter stenosis in all lesions that showed 20% diameter stenosis at baseline or at follow-up as evaluated by quantitative coronary angiography
History
Last registry update
Registered
Primary completion
Started